DDInter1331 DDInter1376
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Olodaterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Olodaterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norfloxacin
Olodaterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Olodaterol {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Olodaterol {u} may lead to a major life threatening interaction when taken with {v} Cocaine
Olodaterol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Olodaterol may lead to a major life threatening interaction when taken with Macimorelin
Olodaterol may lead to a major life threatening interaction when taken with Cocaine